Orphazyme A/S
Investor news
No. 11/2018
Company Registration No. 32266355
Copenhagen, September 20, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that Thomas Kirkegaard Jensen, Chief Scientific Officer at Orphazyme, will be presenting at the 25th NPUK Annual Family Conference 2018 in Wyboston, Bedfordshire, UK, on September 21-22, 2018.
For additional information, please contact
Orphazyme A/S
Anders Hinsby, CEO +45 31 44 31 39
About Orphazyme A/S
Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases. Our research focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit www.orphazyme.com.
Attachment
